The actinic keratosis treatment market size has grown strongly in recent years. It will grow from $3.2 billion in 2024 to $3.44 billion in 2025 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to treatment adherence, market competition, patient education initiatives, dermatological practices, research and clinical trials.
The actinic keratosis treatment market size is expected to see strong growth in the next few years. It will grow to $4.69 billion in 2029 at a compound annual growth rate (CAGR) of 8%. The growth in the forecast period can be attributed to patient education and engagement, digital health integration, growing awareness, focus on preventive dermatology, personalized medicine trends. Major trends in the forecast period include shift towards combination therapies, technological advancements, personalized treatment approaches, increasing incidence rates, minimally invasive treatments.
The escalating prevalence of actinic keratosis is anticipated to drive the growth trajectory of the market for actinic keratosis treatment. Actinic keratosis, a consequence of prolonged sun exposure, manifests as rough, scaly skin patches and necessitates treatment to mitigate precancerous lesions. The surge in actinic keratosis cases underscores the amplified demand for treatment options, driving pharmaceutical research and advocating the use of topical treatments. According to the World Cancer Research Fund International's February 2022 report, the incidence of actinic keratosis surged from over 150,000 new cases in 2020 to 197,700 cases in 2022, emphasizing the pivotal role of treatment advancements in addressing this condition.
The expanding demographic of elderly individuals is poised to be a significant catalyst propelling the growth trajectory of the actinic keratosis treatment market. Addressing the needs of the geriatric populace - typically aged 65 and older - remains pivotal due to their susceptibility to actinic keratosis, attributed to prolonged sun exposure and skin aging. Actinic keratosis treatment interventions are crucial in curbing precancerous skin lesions, consequently reducing the risk of skin cancer among this demographic. As per the World Health Organization's projection in October 2022, the population aged 60 and above is estimated to surge from 1 billion in 2020 to 1.4 billion by 2030, with a subsequent doubling to 2.1 billion by 2050. This demographic shift underscores the necessity for focused treatments catering to the geriatric population susceptible to actinic keratosis.
Major companies in the actinic keratosis treatment market are concentrating on developing innovative products, such as prescription medications, to enhance treatment efficacy, improve patient outcomes, and broaden their product offerings. Prescription medications are drugs that can only be dispensed with a healthcare provider's written authorization, specifying the medication name, dosage, and duration. These drugs are intended for treating specific medical conditions and necessitate careful monitoring due to potential side effects. For example, in December 2022, Biofrontera AG, a Germany-based pharmaceutical company, introduced Ameluz, a topical gel containing 5-aminolevulinic acid. This gel is used in conjunction with photodynamic therapy (PDT) to treat mild to moderate actinic keratoses (AK) and certain types of basal cell carcinoma. The treatment involves applying the gel to the affected skin areas, followed by exposure to light from a BF-RhodoLED lamp, which activates the medication.
Leading companies in the actinic keratosis treatment market are prioritizing advancements in technologies like positioning sensors to boost treatment accuracy, enhance patient outcomes, and optimize therapy delivery by precisely targeting light or topical agents to the affected skin areas. Positioning sensor technology refers to systems that accurately identify the location of an object or surface, often utilized to guide and improve treatment in medical procedures. For example, in December 2022, Biofrontera Inc., a US-based biopharmaceutical firm, introduced the RhodoLED XL Lamp. This lamp is approved for use in conjunction with Ameluz (aminolevulinic acid hydrochloride) topical gel, 10%, to treat mild-to-moderate actinic keratosis on the face and scalp. This approval highlights the lamp's role in enhancing the efficacy of photodynamic therapy (PDT).
In March 2022, Coegin Pharma, a Sweden-based company at the forefront of a phase I/II trial featuring their lead candidate AVX001 targeting actinic keratosis and actively engaged in the preclinical development of AVX420 for conditions like leukemia and chronic kidney disease, executed a merger with Follicum. This strategic alliance aimed to reinforce Coegin Pharma's drug development portfolio by placing a significant emphasis on tackling diabetes complications. Follicum, a biotech company based in Sweden, brings complementary expertise and resources to Coegin Pharma, fortifying its position in drug development and enhancing its focus on addressing various medical conditions.
Major companies operating in the actinic keratosis treatment market are Sun Pharmaceutical Industries Ltd., Novartis AG, Hill Dermaceuticals Inc., Bausch Health Companies Inc., LEO Pharma A/S, Almirall SA, Biofrontera AG, Galderma SA, Mylan NV, Cipher Pharmaceuticals Inc., Pierre Fabre Pharmaceuticals Inc., Tolmar Pharmaceuticals Inc., Stanford Chemicals Company, Glaxo Smith Kline PLC, Alma Lasers Ltd., 3M Company, Nestle SA, Cutanea Life Sciences Inc., DUSA Pharmaceuticals Inc., Foamix Pharmaceuticals Ltd., G&W Laboratories Inc., Hikma Pharmaceuticals PLC, Innocutis Holdings LLC, Mayne Pharma Group Limited, Meda AB, Merz Pharma GmbH & Co KGaA, Perrigo Company PLC, PharmaDerm A division of Fougera Pharmaceuticals Inc., Promius Pharma LLC, Ranbaxy Laboratories Limited, Sandoz International GmbH, Stiefel Laboratories Inc., Teva Pharmaceutical Industries Ltd., Valeant Pharmaceuticals International Inc., Zydus Pharmaceuticals Inc., Dermira Inc., Menlo Therapeutics Inc., Sol-Gel Technologies Ltd., Verrica Pharmaceuticals Inc.
North America was the largest region in the actinic keratosis treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the actinic keratosis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the actinic keratosis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Actinic keratoses treatment addresses the skin condition resulting from sun exposure, primarily manifesting on the face, scalp, backs of the hands, or chest. This treatment aims to mitigate the risk of developing the condition by safeguarding the skin from ultraviolet (UV) rays and minimizing regular sun exposure.
The primary categories of actinic keratosis treatment include topical applications, procedural interventions, photodynamic therapy, and other modalities. Topical treatment involves the application of specific medications like fluorouracil cream, imiquimod cream, ingenol mebutate gel, and diclofenac gel. These medications are utilized across various healthcare settings, including hospitals, private dermatology clinics, laser therapy centers, cancer treatment facilities, spas, rejuvenation centers, and in homecare practices.
The actinic keratosis treatment market research report is one of a series of new reports that provides actinic keratosis treatment market statistics, including actinic keratosis treatment industry global market size, regional shares, competitors with an actinic keratosis treatment market share, detailed actinic keratosis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the actinic keratosis treatment industry. This actinic keratosis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The actinic keratoses treatment market includes revenues earned by entities by providing cryotherapy, laser therapy, chemical peels, and medications. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The actinic keratosis treatment market size is expected to see strong growth in the next few years. It will grow to $4.69 billion in 2029 at a compound annual growth rate (CAGR) of 8%. The growth in the forecast period can be attributed to patient education and engagement, digital health integration, growing awareness, focus on preventive dermatology, personalized medicine trends. Major trends in the forecast period include shift towards combination therapies, technological advancements, personalized treatment approaches, increasing incidence rates, minimally invasive treatments.
The escalating prevalence of actinic keratosis is anticipated to drive the growth trajectory of the market for actinic keratosis treatment. Actinic keratosis, a consequence of prolonged sun exposure, manifests as rough, scaly skin patches and necessitates treatment to mitigate precancerous lesions. The surge in actinic keratosis cases underscores the amplified demand for treatment options, driving pharmaceutical research and advocating the use of topical treatments. According to the World Cancer Research Fund International's February 2022 report, the incidence of actinic keratosis surged from over 150,000 new cases in 2020 to 197,700 cases in 2022, emphasizing the pivotal role of treatment advancements in addressing this condition.
The expanding demographic of elderly individuals is poised to be a significant catalyst propelling the growth trajectory of the actinic keratosis treatment market. Addressing the needs of the geriatric populace - typically aged 65 and older - remains pivotal due to their susceptibility to actinic keratosis, attributed to prolonged sun exposure and skin aging. Actinic keratosis treatment interventions are crucial in curbing precancerous skin lesions, consequently reducing the risk of skin cancer among this demographic. As per the World Health Organization's projection in October 2022, the population aged 60 and above is estimated to surge from 1 billion in 2020 to 1.4 billion by 2030, with a subsequent doubling to 2.1 billion by 2050. This demographic shift underscores the necessity for focused treatments catering to the geriatric population susceptible to actinic keratosis.
Major companies in the actinic keratosis treatment market are concentrating on developing innovative products, such as prescription medications, to enhance treatment efficacy, improve patient outcomes, and broaden their product offerings. Prescription medications are drugs that can only be dispensed with a healthcare provider's written authorization, specifying the medication name, dosage, and duration. These drugs are intended for treating specific medical conditions and necessitate careful monitoring due to potential side effects. For example, in December 2022, Biofrontera AG, a Germany-based pharmaceutical company, introduced Ameluz, a topical gel containing 5-aminolevulinic acid. This gel is used in conjunction with photodynamic therapy (PDT) to treat mild to moderate actinic keratoses (AK) and certain types of basal cell carcinoma. The treatment involves applying the gel to the affected skin areas, followed by exposure to light from a BF-RhodoLED lamp, which activates the medication.
Leading companies in the actinic keratosis treatment market are prioritizing advancements in technologies like positioning sensors to boost treatment accuracy, enhance patient outcomes, and optimize therapy delivery by precisely targeting light or topical agents to the affected skin areas. Positioning sensor technology refers to systems that accurately identify the location of an object or surface, often utilized to guide and improve treatment in medical procedures. For example, in December 2022, Biofrontera Inc., a US-based biopharmaceutical firm, introduced the RhodoLED XL Lamp. This lamp is approved for use in conjunction with Ameluz (aminolevulinic acid hydrochloride) topical gel, 10%, to treat mild-to-moderate actinic keratosis on the face and scalp. This approval highlights the lamp's role in enhancing the efficacy of photodynamic therapy (PDT).
In March 2022, Coegin Pharma, a Sweden-based company at the forefront of a phase I/II trial featuring their lead candidate AVX001 targeting actinic keratosis and actively engaged in the preclinical development of AVX420 for conditions like leukemia and chronic kidney disease, executed a merger with Follicum. This strategic alliance aimed to reinforce Coegin Pharma's drug development portfolio by placing a significant emphasis on tackling diabetes complications. Follicum, a biotech company based in Sweden, brings complementary expertise and resources to Coegin Pharma, fortifying its position in drug development and enhancing its focus on addressing various medical conditions.
Major companies operating in the actinic keratosis treatment market are Sun Pharmaceutical Industries Ltd., Novartis AG, Hill Dermaceuticals Inc., Bausch Health Companies Inc., LEO Pharma A/S, Almirall SA, Biofrontera AG, Galderma SA, Mylan NV, Cipher Pharmaceuticals Inc., Pierre Fabre Pharmaceuticals Inc., Tolmar Pharmaceuticals Inc., Stanford Chemicals Company, Glaxo Smith Kline PLC, Alma Lasers Ltd., 3M Company, Nestle SA, Cutanea Life Sciences Inc., DUSA Pharmaceuticals Inc., Foamix Pharmaceuticals Ltd., G&W Laboratories Inc., Hikma Pharmaceuticals PLC, Innocutis Holdings LLC, Mayne Pharma Group Limited, Meda AB, Merz Pharma GmbH & Co KGaA, Perrigo Company PLC, PharmaDerm A division of Fougera Pharmaceuticals Inc., Promius Pharma LLC, Ranbaxy Laboratories Limited, Sandoz International GmbH, Stiefel Laboratories Inc., Teva Pharmaceutical Industries Ltd., Valeant Pharmaceuticals International Inc., Zydus Pharmaceuticals Inc., Dermira Inc., Menlo Therapeutics Inc., Sol-Gel Technologies Ltd., Verrica Pharmaceuticals Inc.
North America was the largest region in the actinic keratosis treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the actinic keratosis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the actinic keratosis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Actinic keratoses treatment addresses the skin condition resulting from sun exposure, primarily manifesting on the face, scalp, backs of the hands, or chest. This treatment aims to mitigate the risk of developing the condition by safeguarding the skin from ultraviolet (UV) rays and minimizing regular sun exposure.
The primary categories of actinic keratosis treatment include topical applications, procedural interventions, photodynamic therapy, and other modalities. Topical treatment involves the application of specific medications like fluorouracil cream, imiquimod cream, ingenol mebutate gel, and diclofenac gel. These medications are utilized across various healthcare settings, including hospitals, private dermatology clinics, laser therapy centers, cancer treatment facilities, spas, rejuvenation centers, and in homecare practices.
The actinic keratosis treatment market research report is one of a series of new reports that provides actinic keratosis treatment market statistics, including actinic keratosis treatment industry global market size, regional shares, competitors with an actinic keratosis treatment market share, detailed actinic keratosis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the actinic keratosis treatment industry. This actinic keratosis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The actinic keratoses treatment market includes revenues earned by entities by providing cryotherapy, laser therapy, chemical peels, and medications. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Actinic Keratosis Treatment Market Characteristics3. Actinic Keratosis Treatment Market Trends and Strategies4. Actinic Keratosis Treatment Market - Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market32. Global Actinic Keratosis Treatment Market Competitive Benchmarking and Dashboard33. Key Mergers and Acquisitions in the Actinic Keratosis Treatment Market34. Recent Developments in the Actinic Keratosis Treatment Market
5. Global Actinic Keratosis Treatment Growth Analysis and Strategic Analysis Framework
6. Actinic Keratosis Treatment Market Segmentation
7. Actinic Keratosis Treatment Market Regional and Country Analysis
8. Asia-Pacific Actinic Keratosis Treatment Market
9. China Actinic Keratosis Treatment Market
10. India Actinic Keratosis Treatment Market
11. Japan Actinic Keratosis Treatment Market
12. Australia Actinic Keratosis Treatment Market
13. Indonesia Actinic Keratosis Treatment Market
14. South Korea Actinic Keratosis Treatment Market
15. Western Europe Actinic Keratosis Treatment Market
16. UK Actinic Keratosis Treatment Market
17. Germany Actinic Keratosis Treatment Market
18. France Actinic Keratosis Treatment Market
19. Italy Actinic Keratosis Treatment Market
20. Spain Actinic Keratosis Treatment Market
21. Eastern Europe Actinic Keratosis Treatment Market
22. Russia Actinic Keratosis Treatment Market
23. North America Actinic Keratosis Treatment Market
24. USA Actinic Keratosis Treatment Market
25. Canada Actinic Keratosis Treatment Market
26. South America Actinic Keratosis Treatment Market
27. Brazil Actinic Keratosis Treatment Market
28. Middle East Actinic Keratosis Treatment Market
29. Africa Actinic Keratosis Treatment Market
30. Actinic Keratosis Treatment Market Competitive Landscape and Company Profiles
31. Actinic Keratosis Treatment Market Other Major and Innovative Companies
35. Actinic Keratosis Treatment Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Actinic Keratosis Treatment Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on actinic keratosis treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for actinic keratosis treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The actinic keratosis treatment market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) by Treatment: Topical Treatment; Procedural Modality; Photodynamic Therapy; Other Treatments2) by Medication: Fluorouracil Cream; Imiquimod Cream; Ingenol Mebutate Gel; Diclofenac Gel
3) by End User: Hospitals; Private Dermatology Clinics; Laser Therapy Centers; Cancer Treatment Centers; Spas and Rejuvenation Centers; Homecare
Subsegments:
1) by Topical Treatment: 5-Fluorouracil (5-FU); Imiquimod; Ingenol Mebutate; Diclofenac2) by Procedural Modality: Cryotherapy; Curettage and Electrosurgery; Laser Therapy; Chemical Peels
3) by Photodynamic Therapy: ALA-Based PDT; MAL-Based PDT
4) by Other Treatments: Immunotherapy; Phototherapy; Combination Therapies
Key Companies Mentioned: Sun Pharmaceutical Industries Ltd.; Novartis AG; Hill Dermaceuticals Inc.; Bausch Health Companies Inc.; LEO Pharma a/S
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
Some of the major companies featured in this Actinic Keratosis Treatment market report include:- Sun Pharmaceutical Industries Ltd.
- Novartis AG
- Hill Dermaceuticals Inc.
- Bausch Health Companies Inc.
- LEO Pharma A/S
- Almirall SA
- Biofrontera AG
- Galderma SA
- Mylan NV
- Cipher Pharmaceuticals Inc.
- Pierre Fabre Pharmaceuticals Inc.
- Tolmar Pharmaceuticals Inc.
- Stanford Chemicals Company
- Glaxo Smith Kline PLC
- Alma Lasers Ltd.
- 3M Company
- Nestle SA
- Cutanea Life Sciences Inc.
- DUSA Pharmaceuticals Inc.
- Foamix Pharmaceuticals Ltd.
- G&W Laboratories Inc.
- Hikma Pharmaceuticals PLC
- Innocutis Holdings LLC
- Mayne Pharma Group Limited
- Meda AB
- Merz Pharma GmbH & Co KGaA
- Perrigo Company PLC
- PharmaDerm A division of Fougera Pharmaceuticals Inc.
- Promius Pharma LLC
- Ranbaxy Laboratories Limited
- Sandoz International GmbH
- Stiefel Laboratories Inc.
- Teva Pharmaceutical Industries Ltd.
- Valeant Pharmaceuticals International Inc.
- Zydus Pharmaceuticals Inc.
- Dermira Inc.
- Menlo Therapeutics Inc.
- Sol-Gel Technologies Ltd.
- Verrica Pharmaceuticals Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | February 2025 |
| Forecast Period | 2025 - 2029 |
| Estimated Market Value ( USD | $ 3.44 Billion |
| Forecasted Market Value ( USD | $ 4.69 Billion |
| Compound Annual Growth Rate | 8.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 40 |
